CClinicalTrials.gg
Not yet recruitingNCT05824299Updated Aug 9, 2023

Influence of Anesthesia Methods on CTCs in TURBT Patients

An interventional study of General Anesthesia and Spinal Anesthesia in Bladder Cancer, sponsored by RenJi Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-08-09.

Sponsored by RenJi Hospital · Not applicable, Interventional, and Health services research

From the registry’s dates

  • Primary completion was expected by Apr 2024, 2 years 5 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
162
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Multiple lines of evidence have shown that anesthesia method is associated with long-term outcomes in patients undergoing surgery due to cancers, including lung, breast, prostate, and bladder cancer, etc. Circulating tumor cells (CTCs) have been validated as prognostic biomarkers of a number of cancers. The aim of this study is to investigate the effects of anesthesia methods on the number of CTCs in patients receiving transurethral resection of bladder tumor (TURBT). The difference of anesthesia method is achieved by using general anesthesia in one group and spinal anesthesia in the other group.

02

Conditions studied

  • Bladder Cancer

Keywords

  • Circulating Tumor Cells
  • General Anesthesia
  • Spinal Anesthesia
  • Transurethral Resection of Bladder Tumor
03

In context

Urinary Bladder Neoplasms

1,617 studies on the registry are indexed under Urinary Bladder Neoplasms; 422 are open to participants now.

This study's planned enrollment of 162 is above the median of 60 across 1,163 interventional studies indexed under Urinary Bladder Neoplasms.

Browse Urinary Bladder Neoplasms studies →

Lead sponsor

RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. .≤18 Age ≤85,ASAI-III.
  2. .Patients with primary bladder cancer of Stage T1 to T4, who are scheduled for transurethral resection of bladder tumor.
  3. .Written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. History of surgery within 6 months.
  2. Contraindications for spinal anesthesia.
  3. With a history of any other malignancy.
  4. Having received preoperative neoadjuvant therapy.
  5. History of long-term opioid use.
  6. Combined with autoimmune diseases or having a history of prolonged hormone use or immunosuppressant use within 1 year.
  7. Combined with impaired liver function (Child - Pugh C) or renal insufficiency (serum creatinine level over 442μmol•L-1).
  8. Known hypersensitivity or suspected allergy to intervention drugs.
  9. Proposed postoperative admission to ICU.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
162 participants (estimated)

Study arms

  • Active comparator
    General Anesthesia

    Patients in this group will receive general anesthesia during TURBT.

    Procedure: General Anesthesia

  • Experimental
    Spinal Anesthesia

    Patients in this group will receive spinal anesthesia during TURBT.

    Procedure: Spinal Anesthesia

Interventions

  • ProcedureGeneral Anesthesia

    Patients will have TURBT under general anesthesia, which is induced with midazolam, propofol, sufentanil and rocuronium. The patients will be mechanically ventilated with laryngeal mask airway (LMA). Anesthesia will be maintained with sevoflurane/desflurane, propofol and remifentanil.

  • ProcedureSpinal Anesthesia

    Patients will have TURBT under spinal anesthesia. 10\~15mg of 0.5% ropivacaine will be injected in the subarachnoid cerebrospinal fluid at the levels of L2-L3 or L3-L4 in lumbar space. It will numb the nerve supply of the belly, hips, bottom as well as legs. The patient stays awake and won't feel any pain due to operation.

06

What researchers measure

Primary outcomes

  1. the number of Circulating Tumor Cells

    The number of circulating tumor cells will be measured by collecting 5 ml of venous blood sample.

    Time frame: on the Day 7~10 after surgery

Secondary outcomes

  1. Surgeon Satisfaction

    The surgeon satisfaction will be measured with the Likert scale, which ranges from 0 to 50, with a higher score indicating higher satisfaction.

    Time frame: immediately after surgery

  2. Patient Satisfaction

    The patient satisfaction will be measured with the Modified Bauer Scale, which ranges from 0 to 50, with a higher score indicating higher satisfaction.

    Time frame: within 24 hours after surgery

  3. Visual Analogue Scale

    Pain intensity will be assessed using the Visual Analogue Scale, which ranges from 0 to 10, with a higher score indicating greater pain intensity at 24 hours after surgery.

    Time frame: at 24 hours after surgery

  4. Nausea Score

    Nausea score will be assessed using the Numerical Rating Scale, which ranges from 0 to 10, with a higher score indicating greater nausea ou score at 24 hours after surgery.

    Time frame: at 24 hours after surgery

  5. Hospitalization Days

    The length of hospital stay will be recorded.

    Time frame: up to 30 days

07

Study locations

1 site
  • Renji Hospital affliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai 200126, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05824299
Lead sponsor
RenJi Hospital
Responsible party
Jie Tian (Principal Investigator, RenJi Hospital) — Principal investigator
First posted
Apr 21, 2023
Start date
Aug 15, 2023 (estimated)
Primary completion
Apr 30, 2024 (estimated)
Completion
Jun 30, 2024 (estimated)
Last update
Aug 9, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion